Loading...
Market
Takeda's dengue vaccine distributed in over 50 countries by end of 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Takeda Pharmaceuticals official press releases or major healthcare news outlets
Story
WHO Prequalifies Takeda's Second Dengue Vaccine on Wednesday
May 15, 2024, 07:27 PM
The World Health Organization (WHO) has prequalified a new dengue vaccine developed by Takeda Pharmaceuticals on Wednesday. This marks the second dengue vaccine to receive WHO prequalification, aiming to bolster efforts against the disease amid rising outbreaks, particularly in the Americas. The WHO recommends the vaccine for children aged 6 to 16 in areas with high dengue burden and transmission intensity. Dengue, a vector-borne disease transmitted by infected mosquitoes, affects over 100-400 million people globally each year.
View original story
Similar markets
Higher efficacy • 33%
Equal efficacy • 34%
Lower efficacy • 33%
Southeast Asia • 33%
South America • 33%
Central America • 34%
Over 50 countries • 25%
30-50 countries • 25%
10-29 countries • 25%
Under 10 countries • 25%
Brazil • 33%
Mexico • 33%
Another country • 33%
Less than 50 million • 25%
50 to 100 million • 25%
100 to 200 million • 25%
More than 200 million • 25%